We established ReSViNET in 2014, and since 2018, ReSViNET has been a foundation — a financially and otherwise independent regulated entity. Julius Clinical works closely with ReSViNET to provide operational support to RSV clinical trials and observational studies. Our operational team has extensive experience in coordinating these studies, and ReSViNET has access to sites in countries across the globe, providing fast recruitment and high retention rates.
COVID-19 lessons from pandemic to endemic
We presented the webinar COVID-19 lessons from pandemic to endemic. During this webinar Prof. Jerome H. Kim, Director General of the International Vaccine Institute (IVI), discussed: - Pandemic preparedness – lessons learned - Clinical Devel...